The Apple Watch Sold More Than Rolex, Omega and Swatch Combined in Q4Wibbitz

Earlier this year, GenSpera filed a registration statement disclosing plans to raise $7.5 million in a public offering.

GenSpera is in Phase II clinical trials with liver-cancer patients for its lead drug, G-202. Proceeds from this latest offering will go for the development of the drug and general corporate purposes, the company said in a regulatory filing.